FDA Sets September Meeting To Discuss Psychedelic And Other Treatments For PTSD
The U.S. Food and Drug Administration (FDA) has scheduled a public meeting for September 6, 2024, to gather input on potential new treatments for post-traumatic stress disorder (PTSD), including the use of psychedelic drugs. This meeting marks a significant step in the ongoing exploration of psychedelics as viable therapies for mental health conditions, particularly PTSD, a disorder that affects millions of people, including many veterans.
Lykos Therapeutics’ Setback
The FDA’s decision to hold this “hybrid public meeting,” offering both virtual and in-person attendance options, comes shortly after the agency’s surprising rejection of a new drug application from Lykos Therapeutics. The application sought approval for an MDMA-based therapy for PTSD, a treatment …